MannKind Corporation (NASDAQ:MNKD), a small cap biotechnology in Valencia, California, planted the catalytic seeds for revolutionary diabetes treatment more than a decade ago that are now materializing for aggressive growth. In this research report, the author will provide a comprehensive analysis of MNKD through his unique views as a practicing MD, researcher, and investor.
(click to enlarge)
Revolution in Diabetes Mellitus Treatments
The market for diabetes mellitus is increasingly gigantic. Research estimates that over 25 million or 8.3% of the U.S. population have diabetes mellitus in 2011. There are 1.9 million new cases each year. Overweight and obesity are quite common in the U.S. as well as modernizing nations. Being overweight leads to obesity; Obesity leads to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|